JP2015524802A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524802A5
JP2015524802A5 JP2015524305A JP2015524305A JP2015524802A5 JP 2015524802 A5 JP2015524802 A5 JP 2015524802A5 JP 2015524305 A JP2015524305 A JP 2015524305A JP 2015524305 A JP2015524305 A JP 2015524305A JP 2015524802 A5 JP2015524802 A5 JP 2015524802A5
Authority
JP
Japan
Prior art keywords
composition
borrelia
polypeptides
combination
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/050058 external-priority patent/WO2014018274A1/en
Publication of JP2015524802A publication Critical patent/JP2015524802A/ja
Publication of JP2015524802A5 publication Critical patent/JP2015524802A5/ja
Pending legal-status Critical Current

Links

JP2015524305A 2012-07-27 2013-07-11 キメラospa分子を含む組成物およびその使用方法 Pending JP2015524802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676668P 2012-07-27 2012-07-27
US61/676,668 2012-07-27
PCT/US2013/050058 WO2014018274A1 (en) 2012-07-27 2013-07-11 Compositions comprising chimeric ospa molecules and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2015524802A JP2015524802A (ja) 2015-08-27
JP2015524802A5 true JP2015524802A5 (enExample) 2016-08-12

Family

ID=48901170

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524305A Pending JP2015524802A (ja) 2012-07-27 2013-07-11 キメラospa分子を含む組成物およびその使用方法

Country Status (11)

Country Link
US (1) US9023367B2 (enExample)
EP (2) EP2877206B1 (enExample)
JP (1) JP2015524802A (enExample)
KR (2) KR20200068756A (enExample)
CN (1) CN104640563A (enExample)
AU (3) AU2013293448A1 (enExample)
CA (1) CA2879689A1 (enExample)
PL (1) PL2877206T3 (enExample)
RU (1) RU2015106742A (enExample)
SI (1) SI2877206T1 (enExample)
WO (1) WO2014018274A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252844B2 (en) * 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
JP6405103B2 (ja) * 2014-03-18 2018-10-17 日本製粉株式会社 ソバアレルゲン特異的モノクローナル抗体
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CN106771250B (zh) * 2017-01-06 2018-08-21 杭州京北生物科技有限公司 一种用于检测哺乳动物莱姆病的荧光素酶免疫共沉淀试剂盒
EP4132950A1 (en) * 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
CN119173446A (zh) 2022-03-08 2024-12-20 赤盾医疗有限公司 机器人药物制备系统中的流体转移站
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FI933580A7 (fi) 1991-02-15 1993-10-13 Uab Research Foundation Pneumokokkiproteiinin rakennegeeni
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
AU8127494A (en) 1993-11-01 1995-05-23 Associated Universities, Inc. Chimeric proteins comprising borrelia polypeptides: uses therefor
EP0880360B1 (en) 1996-02-12 2002-10-09 Cobra Therapeutics Limited Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
AU4800500A (en) 1999-06-21 2001-01-09 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
ATE381575T1 (de) 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
EP1939294A1 (en) 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
AU2001281145A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
ATE496935T1 (de) 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
US20110105355A1 (en) 2008-04-22 2011-05-05 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
AU2011252844B2 (en) 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2015524802A5 (enExample)
JP2015096557A5 (enExample)
JP2015500827A5 (enExample)
JP2016128513A5 (enExample)
JP2023513720A5 (enExample)
JP2015517488A5 (enExample)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2017524682A5 (enExample)
de Haan et al. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration
JP2015178529A5 (enExample)
JP2016539946A5 (enExample)
RU2015106742A (ru) Композиции, содержащие химерные молекулы ospa и способы их применения
US20150258190A1 (en) Nicotinamide as adjuvant
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2015529677A5 (enExample)
JP2018505882A5 (enExample)
JP2016514713A5 (enExample)
JP2014521605A5 (enExample)
JP2013518052A5 (enExample)
RU2014114506A (ru) Вакцина
JP2017511327A5 (enExample)
JP5766894B2 (ja) ワクチン増強剤としてのαチモシンペプチド
RU2012127358A (ru) Олигопептиды imp-3 и содержащие их вакцины
JP2011525902A5 (enExample)
JP2018536002A5 (enExample)